search
Evorpacept
Trends
- 1ALX Oncology publishes promising evorpacept gastric cancer trial data in Nature Medicine▼ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
ALX Oncology announced that Nature Medicine has published Phase 2 results from its ASPEN-06 trial, showing strong responses and durable clinical benefit with evorpacept combined with trastuzumab and chemotherapy in patients with HER2-positive gastric cancer. The publication adds peer-reviewed weight to the company's lead drug candidate and supports its ongoing development program in gastroesophageal cancers.